Tocagen’s Toca-5 trial has survived two interim reviews, and faces final readout by the end of this year.
The extensively overhauled Tulip-2 study of anifrolumab in lupus is an unexpected success.
Planned divestment of Celgene’s psoriasis blockbuster means instant cashback for Bristol, a result the markets see as a win-win-win.
The Neptune lung cancer study fails, denting yet further Astrazeneca and Bristol-Myers Squibb’s chances of challenging Merck & Co’s Keytruda on the basis of tumour…
Pharmamar says the US FDA has given an accelerated approval filing plan its blessing, and that means a regulatory submission this year.
In blaming bempegaldesleukin’s falling efficacy on poor manufacturing Nektar has alarmed investors even more.
A low-key lung cancer readout approaches for United Therapeutics’ Unituxin, while Biogen hopes to buck the tau trend.
Using EvaluatePharma data Vantage explored investment trends in biopharma and medtech, sales per employee at big drug makers, and the declining number of late-stage…